Regulatory approvals for pharmaceutical candidates developed by Tonix Pharmaceuticals depend entirely on rigorous clinical trial results, safety profiles, and comprehensive reviews conducted by the U.S. Food and Drug Administration. While the company has already achieved significant regulatory success with the official FDA approval of its flagship fibromyalgia treatment, future pipeline candidates targeting conditions like post-traumatic stress disorder, rare genetic diseases, and infectious illnesses must undergo extensive evaluation. The health authorities grant marketing authorization only when empirical data demonstrates that a drug's therapeutic benefits clearly outweigh its known risks, meaning each prospective submission faces independent, rigorous scientific scrutiny.